INVO Bioscience and Alabama Fertility Announce First INVOcell Pregnancy in the State of Alabama
BIRMINGHAM, Ala. and MEDFORD, Mass., June 12, 2018 — INVO Bioscience, Inc. (OTC: IVOB), a medical device company granted FDA clearance for the first Intravaginal Culture System, INVOcell™, today announced that Alabama Fertility, a leading reproductive medicine practice in Birmingham, Alabama, reported the first pregnancy in the State of Alabama utilizing the INVOcell technology.
Beth A. Malizia, MD, a specialist in infertility and reproductive surgery at Alabama Fertility, said, “We are delighted to announce the first INVOcell pregnancy in our clinic and in the state of Alabama. Our patient is 20 weeks pregnant and is doing great. We recently completed a spot on the local evening news – featuring an interview of our patient and images from her ultrasound – that we expect will air next week. INVOcell is a unique, and cost effective, alternative that may produce desired pregnancies where other treatment options have failed. We believe that INVOcell is a great addition to our scope of services.”
Katie Karloff, CEO of INVO Bioscience, commented, “We are pleased that Dr. Beth Malizia and her team have accomplished this important milestone. We greatly appreciate the opportunity to work with them and we look forward to more successful pregnancies in the years to come.”
About Alabama Fertility
At Alabama Fertility we are dedicated to helping patients and couples cope with the often complex problems that can affect reproduction. We support patients with reproductive and hormonal difficulties such as infertility and repeated miscarriages, as well as couples needing advanced fertility treatments or reproductive surgery. We offer the most up-to-date methods of diagnosis and treatment including hormone testing, sonography, assisted reproductive techniques and advanced reproductive surgery and microsurgery. At Alabama Fertility, each patient is treated with the understanding and compassion that these complex reproductive problems require.
About INVO Bioscience
We are a medical device company focused on creating simplified, lower cost treatments for patients diagnosed with infertility. Our solution, the INVO Procedure, is a disruptive new technology. The INVO Procedure is a revolutionary in vivo method of vaginal incubation that offers patients a more natural and intimate experience. Our lead product, the INVOcell, is a patented medical device used in infertility treatment and is considered an Assisted Reproductive Technology (“ART”). The INVOcell is the first Intravaginal Culture (“IVC”) system in the world used for the natural in vivo incubation of eggs and sperm during fertilization and early embryo development, as an alternative to traditional In Vitro Fertilization (“IVF”) and Intrauterine Insemination (“IUI”). Our mission is to increase access to care and expand fertility treatment across the globe with a goal to lower the cost of care and increase availability of care. For more information, please visit http://invobioscience.com/.
Safe Harbor Statement
This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company invokes the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at www.sec.gov. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.
INVO Bioscience, Inc.
Kathleen Karloff, CEO
978-878-9505 ext. 504